A. Kurniawan (Tangerang, Indonesia)

Faculty of Medicine, Pelita Harapan University

Author Of 2 Presentations

 On-Demand ePoster Display

79P - Targeted Intraoperative Radiotherapy vs External Beam Radiotherapy in Early-Stage Breast Cancer Patients: A Systematic Review and Meta-Analysis

Abstract

Background

Targeted Intraoperative Radiotherapy (TARGIT) involves the precise delivery of a large dose of ionizing radiation to the tumor during surgery. TARGIT has emerged as an alternative to Breast External Radiotherapy (EBRT) for women with early breast cancer. However, its efficacy compared to EBRT remain unclear. This systematic review and meta-analysis aimed to evaluate the effectiveness of TARGIT compared to EBRT.

Methods

We searched PubMed, PMC, Science Direct, Google Scholar, and Europe PMC, on January 31st, 2021 using a combination of keywords associated with TARGIT, EBRT, and Breast Cancer concerning their survival rate based on Overall Survival (OS), Mastectomy Free Survival (MFS), Distant Disease-Free Survival (DDFS), and Local Recurrence Free Survival (LRFS). Publications included are limited to English manuscripts with observational design study that were published in the past 10 years. Patients with an incomplete personal or medical information were excluded from this review. All included studies were reviewed by all 6 authors. The quality of each included study was assessed using either the Newcastle-Ottawa Scale (NOS) or Jadad Score and GRADE.

Results

We included a total of 7 studies consisting of 110.532 breast cancer patients. Based on NOS, 3 studies showed good quality. Based on Jadad, 3 studies were good in quality while 1 study was fair. Based on GRADE, these studies were moderate in quality as there was a largely consistent and precise outcome with minimal publication bias. The association of TARGIT and EBRT were found in all included studies. Six studies showed that there is no significant difference between the two groups. However, one study showed that TARGIT was an effective alternative to EBRT. Pooled analysis showed that statistically TARGIT is associated with better OS (HR = 0.96; 95% CI, 0.95 - 0.97; p < 0.00001), MFS (HR = 0.93; 95% CI, 0.77-1.12; p = 0.44), DDFS (HR = 0.92; 95% CI, 0.76-1.12; p = 0.41), and LRFS (HR = 0.99; 95% CI, 0.83-1.17; p = 0,89) when compared with EBRT.

Conclusions

There is no significant difference in survival rate between TARGIT and EBRT. Further reliable research is needed.

Legal entity responsible for the study

Audrey Hadisurya.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Collapse

135P - Relationship between low muscle mass pre-chemotherapy with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy

Abstract

Background

Breast cancer patients undergoing chemotherapy often reported side effects, including fatigue, nausea, vomiting, and unintentional weight loss. Change in body composition, especially decreased muscle mass is known to have important impact of anticancer drug toxicity. Currently, there is still limited data regarding this issue. The aim of the study was to know the relationship between low muscle mass (LMM) and chemotherapy toxicity in breast cancer patients.

Methods

A prospective cohort study of adult women breast cancer was conducted in second cancer referral hospital at Banten, Indonesia. Naïve breast cancer patients were evaluated for LMM using Bio-impedance electrical analysis (BIA) before they underwent chemotherapy. LMM cut off was using Asian working group of sarcopenia criteria <5.7kg/m2. They were followed up for hematological side effects according to common terminology criteria for adverse events (CTCAE) v4.0. Several confounding factors were also evaluated. Chi-square was used to evaluate the relationships between them and continue to logistic regression analysis if the results were significant.

Results

Sixty eight of 128 subjects completed to be evaluated until the end of 3 cycles of chemotherapy. The median of age was 47(25-59) year old. More than half were overweight and obese. Fifty six percent subject were in early stage. The subjects were using either Taxane or Anthracycline based chemotherapy regimen. The menopausal status almost equal. Thirty five percent subject were needed social support. LMM was found in 15(22%) subject. The toxicities mostly anemia and thrombocytopenia were found in 16(23.5%) subject. LMM was associated with toxicities OR(CI) 2.170(1.157-4.068) p<0.000. Early stage was associated with toxicities OR(CI) 1.272 (1.210-2.465) p < 0.000. Body mass index, C-reactive protein, chemotherapy regimen, comorbidity, and performance status were not associated with toxicities. After adjusted with stage and body mass index, LMM still associated with toxicities OR(CI) 6.181(1.494-25.585) p 0.012.

Conclusions

Low muscle mass before chemotherapy was associated with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Collapse

Presenter Of 1 Presentation

 On-Demand ePoster Display

135P - Relationship between low muscle mass pre-chemotherapy with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy

Abstract

Background

Breast cancer patients undergoing chemotherapy often reported side effects, including fatigue, nausea, vomiting, and unintentional weight loss. Change in body composition, especially decreased muscle mass is known to have important impact of anticancer drug toxicity. Currently, there is still limited data regarding this issue. The aim of the study was to know the relationship between low muscle mass (LMM) and chemotherapy toxicity in breast cancer patients.

Methods

A prospective cohort study of adult women breast cancer was conducted in second cancer referral hospital at Banten, Indonesia. Naïve breast cancer patients were evaluated for LMM using Bio-impedance electrical analysis (BIA) before they underwent chemotherapy. LMM cut off was using Asian working group of sarcopenia criteria <5.7kg/m2. They were followed up for hematological side effects according to common terminology criteria for adverse events (CTCAE) v4.0. Several confounding factors were also evaluated. Chi-square was used to evaluate the relationships between them and continue to logistic regression analysis if the results were significant.

Results

Sixty eight of 128 subjects completed to be evaluated until the end of 3 cycles of chemotherapy. The median of age was 47(25-59) year old. More than half were overweight and obese. Fifty six percent subject were in early stage. The subjects were using either Taxane or Anthracycline based chemotherapy regimen. The menopausal status almost equal. Thirty five percent subject were needed social support. LMM was found in 15(22%) subject. The toxicities mostly anemia and thrombocytopenia were found in 16(23.5%) subject. LMM was associated with toxicities OR(CI) 2.170(1.157-4.068) p<0.000. Early stage was associated with toxicities OR(CI) 1.272 (1.210-2.465) p < 0.000. Body mass index, C-reactive protein, chemotherapy regimen, comorbidity, and performance status were not associated with toxicities. After adjusted with stage and body mass index, LMM still associated with toxicities OR(CI) 6.181(1.494-25.585) p 0.012.

Conclusions

Low muscle mass before chemotherapy was associated with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Collapse